Aileron Therapeutics’ ALRN-6924 to be acquired by Advancium Health Network

Aileron Therapeutics (ALRN) and Advancium Health Network, a public charity founded by Deerfield Management and the Deerfield Foundation to meet the needs of underserved patient populations, entered into an exclusive option agreement for the acquisition of ALRN-6924, a clinical-stage oncology agent developed by Aileron prior to its 2023 merger with Lung Therapeutics. During the option period, Advancium intends to evaluate ALRN-6924 as a potential therapy for retinoblastoma, a rare but devastating cancer of the eye. Under the terms of the option agreement, Advancium paid Aileron a non-refundable fee for the exclusive option to acquire ALRN-6924 and related assets. If Advancium exercises its option, Aileron will receive an exercise payment with potential for additional development, regulatory and commercial milestone payments and sales royalties.